The importance of surgical resection in malignant glioma

Current Opinion in Neurology

Volumn 22, Issue 6, 2009, Pages 645-649

  Stummer, Walter ^a   Kamp, Marcel A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Glioblastoma multiforme; Malignant glioma; Prognosis; Surgery

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; AMINOLEVULINIC ACID; HYPOXIA INDUCIBLE FACTOR 1; TEMOZOLOMIDE;

BRAIN BIOPSY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; GLIOBLASTOMA; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PROGNOSIS; REVIEW;

AMINOLEVULINIC ACID; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; NEUROSURGICAL PROCEDURES; PHOTOSENSITIZING AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 74049133168     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283320165     Document Type: Review

References (38)

1. Ramina R, Coelho NM, Giacomelli A, et al. Optimizing costs of intraoperative magnetic resonance imaging. A series of 29 glioma cases. Acta Neurochir (Wien) 2009 [Epub ahead of print]. doi: 10.1007/s00701-009-0430-2.
2. Schneider JP, Trantakis C, Rubach M, et al. Intraoperative MRI to guide the resection of primary supratentorial glioblastoma multiforme: a quantitative radiological analysis. Neuroradiology 2005; 47:489-500.
3. Muragaki Y, Iseki H, Maruyama T, et al. Usefulness of intraoperative magnetic resonance imaging for glioma surgery. Acta Neurochir Suppl 2006; 98:67-75.
4. Hirschberg H, Samset E, Hol PK, et al. Impact of intraoperative MRI on the surgical results for high-grade gliomas. Minim Invasive Neurosurg 2005; 48:77-84.
5. Nimsky C, Ganslandt O, Buchfelder M, Fahlbusch R. Intraoperative visualization for resection of gliomas: the role of functional neuronavigation and intraoperative 1.5 T MRI. Neurol Res 2006; 28:482-487.
6. Gulati S, Berntsen EM, Solheim O, et al. Surgical resection of high-grade gliomas in eloquent regions guided by blood oxygenation level dependent functional magnetic resonance imaging, diffusion tensor tractography, and intraoperative navigated 3D ultrasound. Minim Invasive Neurosurg 2009; 52:17-24.
7. Lindner D, Trantakis C, Renner C, et al. Application of intraoperative 3D ultrasound during navigated tumor resection. Minim Invasive Neurosurg 2006; 49:197-202.
8. Toda M. Intraoperative navigation and fluorescence imagings in malignant glioma surgery. Keio J Med 2008; 57:155-161.
9. Stummer W, Novotny A, Stepp H, et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000; 93:1003-1013.
10. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7:392-401.
11. Whittle IR. Surgery for gliomas. Curr Opin Neurol 2002; 15:663-669.
12. McCarter MD, Fong Y. Role for surgical cytoreduction in multimodality treatments for cancer. Ann Surg Oncol 2001; 8:38-43.
13. Sills AK Jr, Duntsch C, Weimar J. Therapeutic strategies for local recurrent malignant glioma. Curr Treat Options Oncol 2004; 5:491-497.
14. Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 1999; 42:227-231.
15. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
16. Kreth FW, Warnke PC, Scheremet R, Ostertag CB. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 1993; 78:762-766.
17. Ashby LS, Ryken TC. Management of malignant glioma: steady progress with multimodal approaches. Neurosurg Focus 2006; 20:E3.
18. Kowalczuk A, Macdonald RL, Amidei C, et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neuro-surgery 1997; 41:1028-1036.
19. Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people: a randomised study. Acta Neurochir (Wien) 2003; 145:5-10.
20. Quigley MR, Maroon JC. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 1991; 29:385-388.
21. Toennis W, Walter W. Glioblastoma multiforme (report on 2611 cases). Acta Neurochir Suppl (Wien) 1959; (Suppl 6):40-62.
22. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003; 99:467-473.
23. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95:190-198.
24. Albert FK, Forsting M, Sartor K, et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994; 34:45-60.
25. Barker FG, Prados MD, Chang SM, etal. Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 1996; 84:442-448.
26. Vecht CJ, Avezaat CJ, van Putten WL, et al. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry 1990; 53:466-471.
27. Prognostic factors for high-grade malignant glioma. development of a prognostic index. A Report of the Medical Research Council Brain Tumour Working Party. [abstract]. J Neurooncol 2009; 9:47-55.
28. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62:564-576.
29. Pichlmeier U, Bink A, Schackert G, Stummer W. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 2008; 10:1025-1034.
30. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
31. van den Bent MJ, Stupp R, Mason W. Impact of extent of resection on overall survival in newly-diagnosed glioblastoma after chemo-irradiation with temo-zolomide: further analysis of EORTC study 26981 [abstract]. Eur J Cancer 2005; 41:134.
32. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-1280.
33. Evans SM, Judy KD, Dunphy I, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004; 10:8177-8184. (Pubitemid 40053376)
34. Koritzinsky M, Seigneuric R, Magagnin MG, et al. The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother Oncol 2005; 76:177-186.
35. Lal A, Peters H, St Croix B, et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 2001; 93:1337-1343.
36. Collingridge DR, Piepmeier JM, Rockwell S, Knisely JP. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol 1999; 53:127-131.
37. Zagzag D, Zhong H, Scalzitti JM, et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000; 88:2606-2618.
38. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21:1624-1636.